Connecting you to content on EBSCOhost

Works by McClure, Matthew W.

Results: 4

1

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.

Published in:

AAPS Journal, 2019, v. 21, n. 1, p. 1, doi. 10.1208/s12248-018-0272-z

By:

Valade, Elodie;
Kakuda, Thomas N.;
McClure, Matthew W.;
Westland, Christopher;
Valenzuela, Belén;
Ouwerkerk-Mahadevan, Sivi;
Perez-Ruixo, Juan José;
Ackaert, Oliver

Publication type:

Article

2

Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.

Published in:

AAPS Journal, 2018, v. 20, n. 6, p. 1, doi. 10.1208/s12248-018-0271-0

By:

Valade, Elodie;
Valenzuela, Belén;
Kakuda, Thomas N.;
Westland, Christopher;
McClure, Matthew W.;
Ouwerkerk-Mahadevan, Sivi;
Perez-Ruixo, Juan José;
Ackaert, Oliver

Publication type:

Article

3

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.

Published in:

PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0204974

By:

McClure, Matthew W.;
Berliba, Elina;
Tsertsvadze, Tengiz;
Streinu-Cercel, Adrian;
Vijgen, Leen;
Astruc, Béatrice;
Patat, Alain;
Westland, Christopher;
Chanda, Sushmita;
Zhang, Qingling;
Kakuda, Thomas N.;
Vuong, Jennifer;
Khorlin, Nick;
Beigelman, Leonid;
Blatt, Lawrence M.;
Fry, John

Publication type:

Article

4

Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects.

Published in:

Pharmacology Research & Perspectives, 2018, v. 6, n. 3, p. 1, doi. 10.1002/prp2.395

By:

Kakuda, Thomas N.;
McClure, Matthew W.;
Westland, Christopher;
Vuong, Jennifer;
Homery, Marie‐Claude;
Poizat, Gwendoline;
Viguerie, Laure;
Denot, Caroline;
Patat, Alain;
Zhang, Qingling;
Hui, James;
Apelian, David;
Smith, David B.;
Chanda, Sushmita M.;
Fry, John

Publication type:

Article